GSK seeks to market orlistat in Europe
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's marketing application for a 60 mg nonprescription orlistat weight loss product has been accepted for review by the European Agency for the Evaluation of Medicinal Products, the firm announces Oct. 2. GSK seeks a license to market the drug in all 27 EU member countries, though initial launch markets have not been confirmed, the firm notes. Known in the U.S. as alli, the OTC product was approved by FDA in February (1"The Tan Sheet" Feb. 12, 2007, p. 8). On sale in the U.S. since June, alli is the only FDA-approved weight loss product available without a prescription...
You may also be interested in...
Behavioral Science Banner Maps The Future Of GSK Consumer Business
Roger Scarlett-Smith, the new head of GlaxoSmithKline's North American Consumer Healthcare business, believes a nonprescription statin is probably inevitable in the U.S., and his firm still wants to be in early on that opportunity
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.